Literature DB >> 1990864

An evaluation of the use of the Statewide Planning and Research Cooperative System of New York State as a resource planning tool for HIV infection.

G I Kaufman1, G T DiFerdinando, S E Gottesman.   

Abstract

Hospital discharge records of patients with Pneumocystis carinii pneumonia (PCP) in New York State were studied to determine whether cases of human immunodeficiency virus (HIV) infection were identified. We estimate that as many as 13 percent of hospitalizations of patients with PCP in 1987 and 10 percent of those in 1988 were not appropriately identified as HIV related. Identification of PCP as HIV related was a function of a hospital's volume of PCP admissions.

Entities:  

Mesh:

Year:  1991        PMID: 1990864      PMCID: PMC1404952          DOI: 10.2105/ajph.81.2.215

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  3 in total

Review 1.  Pneumocystis carinii.

Authors:  S J Levine; D A White
Journal:  Clin Chest Med       Date:  1988-09       Impact factor: 2.878

2.  Spectrum of pulmonary diseases associated with the acquired immune deficiency syndrome.

Authors:  D E Stover; D A White; P A Romano; R A Gellene; W A Robeson
Journal:  Am J Med       Date:  1985-03       Impact factor: 4.965

3.  Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

Authors:  J A Kovacs; J W Hiemenz; A M Macher; D Stover; H W Murray; J Shelhamer; H C Lane; C Urmacher; C Honig; D L Longo
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

  3 in total
  2 in total

1.  The quality of computerized hospital discharge data.

Authors:  A Muse; P F Smith; J Mikl
Journal:  Am J Public Health       Date:  1992-07       Impact factor: 9.308

2.  Patterns of hospital use by patients with diagnoses related to HIV infection.

Authors:  L J Kozak; E McCarthy; M Moien
Journal:  Public Health Rep       Date:  1993 Sep-Oct       Impact factor: 2.792

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.